Trabectedin is an alkylating drug with a unique mechanism of action causing single-strand and double-strand DNA breaks that activate DNA damage-response pathways. Based on our preclinical data, we hypothesised that poly(ADP-ribose) polymerase 1 (PARP1) inhibitors might be an ideal partner of trabectedin and aimed to assess the safety, identify the recommended phase 2 dose, and explore preliminary signs of activity of trabectedin and olaparib combination treatment in patients with bone and soft-tissue sarcoma.

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group

D'Ambrosio, Lorenzo;Pignochino, Ymera;Miano, Sara;Tolomeo, Francesco;Chiabotto, Giulia;Sangiolo, Dario;Bartolini, Alice;Bardelli, Alberto;Aglietta, Massimo
Last
2018-01-01

Abstract

Trabectedin is an alkylating drug with a unique mechanism of action causing single-strand and double-strand DNA breaks that activate DNA damage-response pathways. Based on our preclinical data, we hypothesised that poly(ADP-ribose) polymerase 1 (PARP1) inhibitors might be an ideal partner of trabectedin and aimed to assess the safety, identify the recommended phase 2 dose, and explore preliminary signs of activity of trabectedin and olaparib combination treatment in patients with bone and soft-tissue sarcoma.
2018
Oct;19
(10)
1360
1371
Tabectedin, Olaparib, sarcomas, TOMAS, ope-label, bone and soft-tissue, phase 1b study, Italian Sarcoma Group
Grignani, Giovanni; D'Ambrosio, Lorenzo; Pignochino, Ymera; Palmerini, Emanuela; Zucchetti, Massimo; Boccone, Paola; Aliberti, Sandra; Stacchiotti, Silvia; Bertulli, Rossella; Piana, Raimondo; Miano, Sara; Tolomeo, Francesco; Chiabotto, Giulia; Sangiolo, Dario; Pisacane, Alberto; Dei Tos, Angelo Paolo; Novara, Luca; Bartolini, Alice; Marchesi, Emanuela; D'Incalci, Maurizio; Bardelli, Alberto; Picci, Piero; Ferrari, Stefano; Aglietta, Massimo
File in questo prodotto:
File Dimensione Formato  
Lancet Oncology 2018f.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 644.63 kB
Formato Adobe PDF
644.63 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Onco-Aglietta.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 642.28 kB
Formato Adobe PDF
642.28 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1678537
Citazioni
  • ???jsp.display-item.citation.pmc??? 37
  • Scopus 62
  • ???jsp.display-item.citation.isi??? 57
social impact